Drugs / HW241045
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07593690 | Jun 2026 → Jan 2027 expected | idiopathic pulmonary fibrosis | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07448194 | Nov 2025 → Jun 2026 overdue | idiopathic pulmonary fibrosis | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HW241045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07448194 ↗ |
| Route | Oral | “Single oral dose of HW241045” NCT07448194 ↗ |